ArticleScientific reports2025
Vitisin A inhibits liver fibrosis by promoting Nrf2/HO-1 pathway and inhibiting Cuproptosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in ferroptosis and cuproptosis: implications for spinal cord injury.Molecular biology reports · 2026Review
- Heat Stress in the Liver of Chicken: Insights from Keap1-Nrf2 Pathway Mediated Ferroptosis and Cuproptosis via the HO-1/FDX1/Gpx4 Axis.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis is a characteristic pathological feature of various chronic liver diseases, which is almost irreversible and intractable. Although many natural components have been shown to have therapeutic effects on liver fibrosis, no studies have examined the effects of Vitisin A on liver fibrosis and the molecular mechanisms involved. In our study, we demonstrated that Vitisin A inhibits liver fibrosis in a concentration- dependent and time-dependent manner. We found that Vitisin A inhibits the Nrf2/HO-1 pathway while inhibiting cuproptosis. We activated cuproptosis and inhibited Nrf2 expression separately, and found the inhibition of hepatic fibrosis by Vitisin A was blocked. The inhibitory effect of Vitisin A on mice model of liver fibrosis was also observed. Interestingly, Vitisin A significantly restored cell viability in liver injury cell model. In conclusion, this study suggests that Vitisin A is a promising therapeutic drug for the treatment of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.